A diverse set of root causes means that there is no single "silver bullet" solution to ending drug shortages. We believe it is an "all-hands-on-deck" effort and will require all stakeholders to work together to address the problem.
McKesson advocates for public policy proposals that will prevent or mitigate shortages in the future, including:
- Reimbursement and market access incentives
- Supply preservation programs
- Supply chain visibility
Learn more ways McKesson is engaging with policymakers on issues impacting the healthcare landscape at our Public Policy page.
Healthcare Distribution Alliance
The Healthcare Distribution Alliance (HDA) is an industry trade organization that advocates for sound public policy supporting patient access to medicines and medical products while preserving the safety and efficiency of the pharmaceutical supply chain. HDA works to educate policymakers, regulators and other stakeholders on the unique drivers of drug shortages, and, to advance solutions on behalf of our industry to manage and mitigate future supply disruptions.
As a member of the HDA, McKesson’s President of U.S. Pharmaceutical Kirk Kaminsky serves as chairman of HDA’s Board of Directors.
Health Industry Distributors Association
Since 1902, the Health Industry Distributors Association (HIDA) has been a leading trade association representing distributors serving healthcare providers. HIDA’s membership represents a network of more than 500 distribution centers nationwide serving more than a half a million sites of care. Distributors are enhancing access, improving patient care, managing healthcare costs, and building partnerships with healthcare providers and government agencies.
HIDA advocates on a wide range of legislative and regulatory issues impacting the healthcare distribution industry, including supply chain resiliency.
Brad Hilton, McKesson’s senior vice president of Medical-Surgical, serves on the HIDA Board of Directors.